Cancer Center Amsterdam

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Saberi Hosnijeh, F., van der Straten, L., Kater, A. P., van Oers, M. H. J., Posthuma, W. F. M., Chamuleau, M. E. D., Bellido, M., Doorduijn, J. K., van Gelder, M., Hoogendoorn, M., de Boer, F., te Raa, G. D., Kerst, J. M., Marijt, E. W. A., Raymakers, R. A. P., Koene, H. R., Schaafsma, M. R., Dobber, J. A., Tonino, S. H. & Kersting, S. S. & 2 others, Langerak, A. W. & Levin, M.-D., Sept 2020, In: Experimental hematology. 89, p. 55-60.e6

Research output: Contribution to journal › Article* › Academic › peer-review

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

Leeksma, A. C., Taylor, J., Wu, B., Gardner, J. R., He, J., Nahas, M., Gonen, M., Alemayehu, W. G., te Raa, D., Walther, T., Hüllein, J., Dietrich, S., Claus, R., de Boer, F., de Heer, K., Dubois, J., Dampmann, M., Dürig, J., van Oers, M. H. J. & Geisler, C. H. & 11 others, Eldering, E., Levine, R. L., Miller, V., Mughal, T., Lamanna, N., Frattini, M. G., Heaney, M. L., Zelenetz, A., Zenz, T., Abdel-Wahab, O. & Kater, A. P., Feb 2019, In: Leukemia. 33, 2, p. 390-402 13 p.

Research output: Contribution to journal › Article* › Academic › peer-review

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

HOVON CLL study group, 1 Jan 2019, In: Haematologica. 104, 1, p. 147-154 8 p.

Research output: Contribution to journal › Article* › Academic › peer-review